Recommendations for permanent prostate brachytherapy with ¹³¹Cs: A consensus report from the Cesium Advisory Group

• Financial disclosure: The randomized trials included in this report were supported by research grants from IsoRay Medical, Richland, WA (IsoRay). When necessary, travel to attend one CAG meeting was provided by IsoRay. An honorarium was paid by IsoRay to some of the members to attend one of the meetings (SB, BM, RP, MR). Several members are paid consultants for IsoRay (BP, MR, SK, RP). None of the authors are employees, none have received any stock ownership, nor provided expert testimony, nor patent applications for IsoRay.

☆☆ Although IsoRay provided funding for the clinical trials referred to in the report, IsoRay provided no assistance with study design, data collection, analysis, data interpretation, report writing, or decision to submit the report for publication.

PII: S1538-4721(08)00589-8

doi: 10.1016/j.brachy.2008.05.004